Abstract: Correct organization of the vascular tree requires the balanced activities of several signaling pathways that regulate tubulogenesis and vascular branching, elongation, and pruning. When this balance is lost, the vessels can be malformed and fragile, and they can lose arteriovenous differentiation. In this review, we concentrate on the transforming growth factor (TGF)-β/bone morphogenetic protein (BMP) pathway, which is one of the most important and complex signaling systems in vascular development. Inactivation of these pathways can lead to altered vascular organization in the embryo. In addition, many vascular malformations are related to deregulation of TGF-β/BMP signaling. Here, we focus on two of the most studied vascular malformations that are induced by deregulation of TGF-β/BMP signaling: hereditary hemorrhagic telangiectasia (HHT) and cerebral cavernous malformation (CCM). The first of these is related to loss-of-function mutation of the TGF-β/BMP receptor complex and the second to increased signaling sensitivity to TGF-β/BMP. In this review, we discuss the potential therapeutic targets against these vascular malformations identified so far, as well as their basis in general mechanisms of vascular development and stability. (Circ Res. 2017;121:981-999.
V ascular malformations constitute an emerging area of research in vascular biology. The wide variety and number of signaling pathways implicated underline the complexity of the mechanisms that orchestrate the correct organization of the vascular tree. An accurate analysis of the different signaling pathways implicated will help not only in the discovery of novel effectors but also, and more importantly, in the definition of therapeutic targets for prevention or reduction of disease progression. Among the major pathways required for the correct architecture of the vascular tree in this review, we focus on transforming growth factor (TGF)-β/bone morphogenetic protein (BMP) signaling. Inactivation of several members of these pathways leads to altered vascular organization in the embryo and the adult, and the number of vascular malformations related to deregulated signaling of TGF-β/BMP is remarkably high. 1 Here, we focus mostly on 2 of the most studied and diffuse malformations: hereditary hemorrhagic telangiectasia (HHT) and cerebral cavernous malformation (CCM). In general, these 2 diseases are caused by 2 opposing conditions relating to TGF-β/BMP signaling: gain-of-function in CCM and loss-of-function in HHT. Here we define the altered signals involved in these malformations and discuss their related therapeutic targets. This comparison also provides insight into the general mechanisms that regulate key aspects of vascular development, including tubulogenesis, vascular stability, arteriovenous differentiation, and capillary fusion.
TGF-β/BMP Signaling
Across the animal kingdom, the TGF-β family has seen transversal evolutionary preservation, and it comprises a large family of ligands that act on virtually all cell types within the body. 2, 3 This pathway produces a diverse and intricate set of cellular development and homeostasis responses and is also involved in pathological conditions. Endothelial cells (ECs) are no exception here, and strong evidence arising from genetic, pharmacological, and histopathologic studies supports a critical role for TGF-β/BMP signaling in the vasculature.
Deregulation of the sophisticated fine balance of TGF-β/ BMP signaling in ECs can lead to the development of vascular syndromes and severe hemorrhaging in pathologies such as HHT, CCM, and aortic aneurisms. On one hand, loss-offunction of ALK1 (activin receptor-like kinase 1) and endoglin (ENG), as 2 important receptors that are predominantly expressed in the endothelium, is associated with the vascular syndrome HHT, 4 with arteriovenous malformations (AVMs) in lung, brain, spinal cord, gastrointestinal tract, and liver that can cause severe hemorrhaging. 4 On the other hand, loss-offunction of any of the CCM genes leads to endothelial-tomesenchymal transition (EndMT) via exacerbation of TGF-β/ BMP signaling, which ultimately contributes to the development of brain cavernomas, with local increased permeability and hemorrhaging in the central nervous system (Figure 1 ). September 29, 2017 deregulated TGF-β/BMP signaling. Large controversy has surfaced because of contrasting results showing TGF-β/BMP either as protective or as instigator of aortic aneurysms 9-11 -a problem not uncommon when discussing TGF-β/BMP signaling pathway.
All in all, despite the large number of studies designed to unravel the importance of TGF-β/BMP family signaling, its precise function in ECs is still difficult to decipher. TGF-β/ BMP signaling seems to be highly context dependent because of a multitude of ligands and receptors that can influence the final outcome. Although emerging often as an attractive pharmacological target, it is important to consider the different aspects of the TGF-β/BMP pathway and to understand how wide and intricate TGF-β/BMP spectrum of action is.
Molecular Features of the TGF-β/BMP Signaling Pathway in ECs
On its secretion and enzymatic activation, the mature TGF-β ligand initiates signaling through recruitment of specific serine/ threonine kinase type I and type II receptor hetero-tetrameric complexes. 12, 13 In ECs, one target for TGF-β activation was originally shown to be the type I receptor ALK5, which is ubiquitously expressed and plays an important role in vascular responses. A second target for TGF-β activation was shown to be the predominantly EC-restricted type I receptor ACVRL1 or ALK1 ( Figure 2 ). Depending on which type I receptor is activated by TGF-β in the endothelium, different Smad-signaling cascades are recruited and activated. Here, ALK1 activation induces phosphorylation of Smad1/5/8, whereas ALK5 activation leads to Smad 2/3 stimulation. [14] [15] [16] After the commitment of either of these Smad pathways, these receptor-activated Smads then form a heteromeric complex with a common molecule, Smad4, which translocates the Smad complexes into the nucleus. [17] [18] [19] Once in the nucleus, endothelial-specific transcriptional modulators are engaged to activate or repress transcription of specific target genes that modulate vascular responses.
1,3 Among ALK1 and ALK5 target genes are the inhibitory Smads, that is, Smad6 and Smad7, respectively. This set of Smads represents a self-regulatory loop for ALK1 and ALK5 signaling. Inhibitory Smads prevent the activation of receptor-regulated Smads by means of competition for type I receptor binding or recruitment of specific ubiquitin ligases or phosphatases, thereby targeting the receptor for proteosomal degradation or dephosphorylation. [20] [21] [22] This description of TGF-β signaling activation is, however, a simplistic summary of the complex TGF-β/BMP signaling features in ECs. TGF-β is the prototypical cytokine of an extensive ligand group that includes not just 3 TGF-βs (TGF-β1-3) but also the BMPs, activins, nodal, inhibins, and the growth and differentiation factors. This large collection of ligands can in turn elicit a multitude of signaling responses through the initial activation of 1 of 5 possible type II receptors (ie, TGF-βRII, BMPRII, ActRIIa, ActRIIb, and AMHRII) and then the recruitment of 1 of 7 type I receptors, ALK1-7.
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Different ligand-receptor II-receptor I combinations can, thus, be assembled triggering different cellular responses, which highlights the potential complexity of the signaling within the TGF-β/BMP family. For example, in early stages of blood vessel formation, the proangiogenic BMP signaling mediated by BMP2 or BMP6 prevails via engagement with ALK2 or ALK3 receptor complexes, 24, 25 whereas BMP9/BMP10 antiangiogenic signaling mediated via ALK1 is predominant during vascular remodeling and maturation. 26, 27 Intriguingly, and representative of the complex nature of this pathway, ALK2, which primarily propagates BMP6 signal, can also function as a receptor for BMP-9. 28 Additionally, there are accessory receptors, which include endoglin (predominantly expressed in ECs) and betaglycan/ TGF-βRIII. [29] [30] [31] Although these receptors do not have kinase activity, 14 they can still have a strong influence over the signaling cascade through their modulation of the activities of the type I and II receptors.
Increasing attention has been concentrated on the ECspecific TGF-β receptors ALK1 and endoglin. Not only their impaired function has severe repercussions on the development of the human syndrome HHT, but they also represent interesting therapeutic targets under pathological conditions, where their expression is upregulated. Example of that are cancers and inflammation. [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] Endoglin is a coreceptor that specifically promotes TGF-β family signaling via ALK1. 44 In this way, ALK1 and endoglin are believed to work together, to promote the same signaling pathway.
Survey of the TGF-β/BMP Members Who Have Been Shown to Play in ECs Based on In Vivo Evidences
ALK1 was long considered an orphan receptor. The TGF-β1 and TGF-β3 isoforms were proposed as ligands for ALK1 and endoglin together, in a complex with ALK5. 16, 44, 45 However, BMP9 and BMP10 were later shown to bind ALK1 with much higher affinity. [46] [47] [48] Since then, many studies have provided further evidence that BMP9 and BMP10 are the 2 major ligands for ALK1, which has had important repercussions on the knowledge of, and research into, HHT. 26, 27, 49, 50 BMP10 binds to ALK1 with slightly lower affinity than BMP9, 47 and in mice, BMP10 is mainly expressed in the embryonic and postnatal heart. 51 The lethal impairment of cardiac development defined for Bmp10 knock-out (KO) mice suggests a cardiac-specific role for BMP10 signaling. 51 However, a direct effect of BMP10 on the vasculature should not be disregarded because circulating BMP10 has been shown to act through ALK1 to mediate flow-dependent arterial quiescence in zebrafish 50 and to cooperate with, or even compensate for, BMP9 signaling through ALK1. BMP10 is removed from the circulation, such as by the introduction of a soluble ALK1-Fc fusion protein or a neutralizing antibody against BMP10. In such cases, this inhibition of both BMP9 and BMP10 signaling reveals impairment of retinal vascularization and defective closure of the ductus arteriosus. 26, 49 These data, thus, sustain a cooperative or compensatory role for BMP9 and BMP10 in vascular remodeling via the ALK1 receptor. They may also have temporalspecific function. BMP10 is believed to be expressed earlier during embryonic development where it plays a key role, and later, BMP9 expression starts taking place when both ligands play an essential function in vascular development in an interchangeable fashion, especially in the maintenance of vascular quiescence. 52 Despite the vast evidence for BMP9 activity as promoter of vasculature stability, 53 there are, although, reports for a proangiogenic role in vitro and in vivo in tumors and age-related macular degeneration. 34, 54, 55 EC-specific, BMP9/ALK1-induced Smad1/5 target genes have been described. BMP9/ALK1 signaling has been associated to upregulation of Notch signaling-related genes (Hes1, Hey1, Hey2, and Jag1) and EphrinB2, Endoglin, Tmem100, and the vasoconstrictor Endothelin-1 on one hand 26,27,56-60 and downregulation of E-Selectin, Cxcr4, and Apelin on the other Figure 1 . Effects of deregulated TGF-β (transforming growth factor-β)/bone morphogenetic protein (BMP) signaling in hereditary hemorrhagic telangiectasia (HHT) and cerebral cavernous malformation (CCM). Loss-of-function and gain-of-function of TGF-β/ BMP both disturb endothelial cell homeostasis, which leads to different dysfunctional phenotypes. For HHT, loss-of-function mutations in Alk1 and Endoglin induce hypersprouting, increased vessel permeability, hyperproliferation, and vessel dilation. For CCM, sustained response to exogenous TGF-β, without variation in receptors level, and subsequent Klf4-driven increased expression of BMP2 and BMP6 ligands induce junction dismantling, increased vessel permeability, hyperproliferation, and acquisition of mesenchymal markers. These all contribute to the formation of either arteriovenous malformations or mulberry-like, multilumen cavernomas. Effective therapies should stabilize and induce regression of the preexisting malformations. EC indicates endothelial cell. September 29, 2017 hand. 26, 37 All in all, these genes can further support the vascular dilation induced on impairment of ALK1 signaling.
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Tmem100 has been described as a novel gene that is enriched in endothelium activated by BMP9 or BMP10 through the ALK1 receptor. 62, 63 Interestingly, Tmem100-null mice die in utero because of impaired differentiation of the arterial endothelium and defects in vascular morphogenesis; this closely phenocopies Alk1 constitutive KO mice. 62, 64, 65 Lack of arteriovenous specification is also a key element in HHT. Tmem100-null mouse embryos also show impairment of EndMT during atrioventricular cushion formation.
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ALK1 and endoglin expression overlap with sites of active vasculogenesis and angiogenesis in early mouse development and during pathogenesis. 35, 40, [67] [68] [69] [70] Development of an Alk1-LacZ knock-in mouse revealed that Alk1 is primarily expressed in developing arterial endothelium, with little or no Alk1 expression in the capillaries. 70 Nonetheless, using immunohistochemistry, ALK1 has been detected in veins, arteries, and capillaries in neonatal retinal vasculature. 24 During mouse postnatal development, Alk1 expression is attenuated, except for lung endothelium. 70 Alk1 is, thus, expressed at low levels in most adult blood vessels. 70 Nonetheless, this low ALK1 expression is enough to keep the adult vasculature quiescent via BMP9/ALK1 signaling. 53 Alk1 expression is instead induced during the neoangiogenic processes, which include wound healing and tumorigenesis. 40, 70 A recent study indicated that Alk1 expression is highly dependent on blood flow, 71 where Alk1-positive ECs align against the direction of blood flow. 72 In ECs deficient for ALK1, alterations in EC migratory patterns result in imbalanced distribution of cells within the vascular network, which favors the formation of enlarged vessels and AVMs. 72 Incidentally, the formation of AVMs in the retina of neonatal Alk1-deficient mice occurs predominantly in regions of higher blood flow. 73 Increased fluid shear stress derived from high blood flow increases the association of endoglin to ALK1 sensitizing ECs to low concentrations of BMP9. 74 In this process, endoglin acts as the flow-specific component.
In its turn, endoglin deficiency affects cell shape and size and VEGF (vascular endothelial growth factor)-induced migration, essential for proper blood flow and vessel remodeling and, therefore, inducing the formation of shunts (sharp commentary on the subject 75 ). 76, 77 During development, with the increase in flow-induced shear stress, the small vessel diameter of normal vessels is accomplished by concomitant EC elongation. Endoglin-mutant ECs are unable to sense and adapt to the fluid shear stress. 77 The flow-regulated shear stress-sensing gene Klf2 is, however, not affected on loss of endoglin. 77 Alk1 or endoglin loss-of-function block the flowinduced vascular stabilization.
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ALK1 and Endoglin Disrupted Signaling: Loss-of-Function and Vascular Development
Alk1 and Eng KO mice die at midgestation because of severe vascular abnormalities, which include excessive capillary fusion, hyperdilation of vessels, hypersprouting, and deficiency of differentiation and recruitment of vascular smooth muscle cells. 64, 65, [79] [80] [81] However, mice that lack 1 copy or have neonatal (1 day postnatum [dpn]), EC-specific deletion of either Alk1 or Eng genes display the HHT patient phenotype. 56, [82] [83] [84] EC-specific deletion of the Alk1 gene (Alk1 EC-KO) at postnatal day 6 leads to respiratory distress and rapid mortality within 48 hours on tamoxifen injection. 56 Analysis of Alk1 EC-KO mice 40 hours after the induction of this gene deletion and before the associated respiratory problems emerge, reveal AVMs, enlarged veins, and hyperbranching of the capillary plexus in the neonatal retina. Consistent with this phenotype, Alk1-deficient ECs display increased migratory properties in vitro and in vivo. 85, 86 Although the pericyte coverage appeared normal at the migration front of the retina, the capillaries in the central region of the capillary plexus showed less pericyte coverage. The ECs within the AVMs of these Alk1 EC-KO mice showed retention of the expression of the venous marker EphB4, but loss of the arterial marker Jag1, which suggested venous-specific development and loss of arterial identity. 56 Interestingly, purified retinal ECs from Alk1 EC-KO mice showed a significant decrease in Sox17 gene expression, 84 which is a critical transcription factor that orchestrates arterial specification. 87 Endoglin was the most strikingly reduced gene in the tested array, 56 and it was also reported previously as a target gene for the BMP9/ALK1 signaling pathway. 41, 59 This observation fits with a feedback loop where endoglin promotes ALK1 signaling, which in turn increases endoglin expression. This raises the question whether the ALK1 mutant phenotype in patients with HHT actually results from loss of endoglin.
Alk1 deletion in mice at embryonic day 17 results in neonatal lethality at 5 dpn, when the mice pups show hemorrhaging in the brain, lungs, and gastrointestinal tract. 82 In attempts to evaluate the ALK1 contribution to vascular homeostasis in adulthood, the deletion of Alk1 in adult mice results in severe internal hemorrhaging in the lungs, small intestine, cecum, and in uterine blood vessels. 56, 82 Consistent with the genetic studies, inhibition of ALK1 signaling in neonatal mice using a soluble ALK1 extracellular domain efficiently impairs retinal neonatal angiogenesis, inducing hypervascularization and the appearance of AVMs. 26, 27 These data, thus, suggest that ALK1 signaling is tightly bound to EC maturation, vessel integrity, and stability. Nonetheless it is plausible that this pathway functions as a trigger that activates other critical angiogenesis regulators, such as VEGF, Notch, angiopoietin 2, and even other proangiogenic BMPs, such as BMP2 and BMP6. 22 Of note, Notch regulates ECs responsiveness to BMP2 and BMP6 via the inhibitory Smad, Smad6, which in turn acts upstream of target gene activation and regulates new vessel branch formation. 88 How Smad6 regulates disturbed ALK1/endoglin signaling in patients with HHT is currently not known.
As for ALK1, endoglin has also been reported for active sites of angiogenesis. 89 Endothelial-specific loss-of-function for endoglin can delay remodeling in the capillary plexus and increase proliferation within AVMs of the neonatal retina. 83 The AVMs formed in these Eng EC-KO mice show venous markers, such as EphB4 and the Apelin receptor, but lack the arterial markers Jag1 and EphrinB2. The dilation of arterioles as an initial step for AVM formation was first described for cerebral AVMs in endoglin heterozygous mice. 90 Here, rounder endothelial nuclei shape and irregular cellular orientation deviating from that of the blood flow decreased arteriolar constriction and shear stress, suggested to be the cause for arteriolar dilation. Recently, an elegant study by Jin et al 76 showed that AVMs originate in the arterioles using a mouse model for HHT1. Three days after endothelial-specific deletion of endoglin, the arterioles present with visible enlargement, and 6 days after tamoxifen injection, the AVMs are more numerous and obvious, gradually expanding to become arteriovenous shunts. Despite the arteriolar origin, the AVMs present venous characteristics, highlighted by reduced DLL4 expression and by the venous-typical coverage by α-smooth muscle actin expressing cells. In the formation of AVM, lack of flow-mediated venous-to-arterial migration and increased activation of Akt downstream VEGFR2 play crucial roles. 76 No detectable change in downstream phosphorylation of either Smad2 or Smad1/5/8 is, however, observed in Eng EC-KO mice, 83 suggesting activity from alternative nonclassical TGF-β/BMP pathways. 91 Alternative pathways may, therefore, redirect the signaling events while still additively contributing to the defects associated with endoglin ablation.
Interestingly, the inhibitory effect on the migration of ECs exerted by ALK1 may also be Smad-independent because the BMP inhibitory Smad6 is unable to counteract constitutively active ALK1-induced inhibition of cell migration in a wound closure assay while it impaired ALK1-induced Smad1/5/8 pathway activation and downstream target gene transcription. 86 Data on TGF-β/BMP signaling in patients with HHT are scarce because of the rare nature of this disorder. Nevertheless, a few studies that looked at mRNA expression and long noncoding RNAs reported some attenuation of TGF-β/BMP signaling derived from ALK1 and endoglin loss-of-function mutations. [92] [93] [94] [95] In endoglin heterozygote patients, endoglin levels are decreased to 50%. However, this reduction occurs evenly throughout all endothelium of the patients with HHT and is not limited to the lesional area. 96 In patients with HHT, only selected vascular beds develop telangiectasis or AVM lesions, whereas other areas remain normal (>99.9%). 97 Given that the AVMs occur only in a few areas of the patient vasculature, one might speculate the need of a second-hit mutation or stimuli, such as VEGF, that triggers the development of AVMs. 98 Interestingly, focal presence of VEGF in adult mice causes more severe cerebral vascular dysplasia than Eng fl/fl or Alk1 fl/fl mice injected with adenoviral-Cre only, corroborating the second-hit theory as necessary for the development of a fully formed AVM in adult mice.
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Hereditary Hemorrhagic Telangiectasia Clinical Features of HHT
Hereditary hemorrhagic telangiectasia is also known as Rendu-Osler-Weber syndrome, and it is an inherited pathological vascular condition that is associated with disrupted TGF-β signaling in ECs. HHT is an autosomal dominant disorder that has been estimated to occur in 1.25 to 2 in 10 000 individuals. 101, 102 The diagnosis of HHT currently remains at the clinical level. The consensus clinical criteria, which are known as the Curaçao criteria, are epistaxis (ie, spontaneous, recurrent nosebleeds), telangiectases (ie, multiple distended blood capillaries at characteristic sites, such as lips, oral cavity, fingers, and nose), visceral lesions (ie, AVMs in lung, brain, liver, and spinal cord), gastrointestinal bleeding, and a family history of the disease. 103 The diagnosis is definite if at least 3 of these criteria are met, whereas it is possible or suspected if 2 of them are met, and unlikely if <2 are met. 4 Recurrent and severe epistaxis because of the presence of telangiectasias in the nasal September 29, 2017 mucosa is the most common presentation of HHT (>95% of patients), 4 which frequently leads to severe anemia, at which time intravenous iron and blood transfusions become necessary. Although not life threatening, severe epistaxis has a great impact on the quality of life of patients with HHT, and it often represents their major hindrance to everyday life activities. 4 Telangiectases can present with different degrees of severity, although they usually develop suddenly. They tend to become more numerous over time and occur predominately in the skin and oral cavity. AVMs are larger vascular malformations occurring prevalently in the lung, liver, and brain. AVMs can spontaneously disappear or recur after surgery, radiosurgery, or endovascular therapy. 104 These events, thus, suggest that the malformations are plastic, dependent on autocrine or paracrine signaling, and constantly under remodeling. Small telangiectases result from the emergence of direct connections between a small artery and a vein, with the concomitant loss of the associated bed of capillaries. Larger and more severe AVMs form because of shunts between the high-pressure arterial system and the low-pressure venous network, which exposes these vascular lesions to high risk of hemorrhagic rupture. This more often occurs in the lungs, liver, and brain of patients with HHT and can eventually cause mortality. 101, 105, 106 The Curaçao criteria are particularly helpful to distinguish between affected and nonaffected adults. However, special attention must be paid to the risk of not diagnosing HHT in asymptomatic children and young adults. In these cases, not all of the typical symptoms might be present because most patients show full penetrance of HHT only around the age of 40 years. 101, 103 Here, we emphasize the benefit and importance of genetic screenings for early detection and diagnosis of the disease, especially important in families affected by HHT.
Genetic Aspects of HHT Development
At least 5 forms of HHT have been described. 107 The vast majority of patients with HHT show the HHT1 or HHT2 form, and they develop this condition because they carry loss-of-function germline mutations in 2 predominantly endothelial genes: the coreceptor endoglin 108 and the type I receptor for the TGF-β/ BMP superfamily, ALK1, 109 respectively, and collectively present in 85% of the patients. 110 Two additional abnormal loci have been identified for HHT3 and HHT4, but these remain uncharacterized to date. 111, 112 More recently, mutations on BMP9 (HHT5 or HHT-like), the major ligand for ALK1/endoglin receptor activation, have also been described. 52, 107, 113, 114 Interestingly, 15% to 20% of HHT-causing mutations remain to be described, 110 which suggests that there are uncharacterized mutations in other genes involved in HHT or in transcription regulatory regions of the described genes. 115 These might comprise common mutations with discrete vascular disorder phenotypes or even vascular syndromes with overlapping phenotypes. 113 Additionally, there is a syndrome that arises from the rare combination of juvenile polyposis and HHT that is because of mutations in SMAD4 (1%-2% of patients with HHT)-the central molecule in the TGF-β/BMP signaling cascade. 116, 117 Unfortunately, many patients who have suspected HHT do not present a clear diagnosis, or do not show pathogenic mutations in HHT genes, which defines the need to investigate additional biomarkers of HHT.
Pulmonary and cerebral AVMs occur more often in HHT1 (which is caused by mutation of ENG), whereas hepatic AVMs are more frequent in HHT2 (which is caused by mutation of ALK1). 103, 105, 118, 119 The specific expression of the ALK1 ligand, BMP9, predominantly in the liver may reflect a tissue-specific manifestation in HHT2 (Table 1) . 120 
Biomarkers and Treatment of HHT
The definition of reliable biomarkers of HHT is important for prediction of the outcome of this disease, to follow the effects of treatments, and in general, for more complete diagnosis. Several HHT biomarkers and novel methodological approaches have been suggested during the last few years.
HHT has several possible biomarkers that can be easily detected during a simple blood test, such as soluble proteins in the plasma (ie, VEGF, TGF-β, soluble endoglin, angiopoietin-2, factor VIII, and von Willebrand factor) and noncoding small RNAs (microRNAs: ie, miR-27a, miR-205, and miR-210) that take part in post-translational gene regulation. 107, 110, 130, 135, 136 On the contrary, differential HHT gene expression fingerprinting, next-generation sequencing of a panel of genes involved in HHT, and infrared spectroscopy combined with artificial neural network patterns have also been established. 92, 110 These studies, thus, provide hints for novel involvement of and connections with other pathways. This is the case for Wnt signaling, which shows differential expression in nasal telangiectasias of patients with HHT1 similarly to TGF-β/BMP signaling. 92 Wnt and TGF-β/BMP signaling pathways cross talk has been identified; 131 however, how they interact and regulate each other is still poorly understood. Given their coexistence in central mechanisms of developmental and pathological conditions, it is likely that these 2 pathways have close interaction with important consequences to the development of vascular conditions, such as HHT.
Recently, Tabruyn et al 130 characterized a signature for circulating microRNAs that appears to help in the identification of patients with HHT. The levels of miR-27a were significantly higher in patients with HHT compared with control subjects, and miR-205 was significantly downregulated. MiR-27 has been described previously as a proangiogenic microRNA. 138 miR-205 has been shown to reduce EC proliferation, migration, and tube formation. 130 In addition, the expression of miR-205 modulates the TGF-β signaling pathway through the inhibition of Smad1 and Smad4, shifting the TGF-β signaling activity toward ALK5. The combination of these microRNAs (ie, miR-27 and miR-205) might be useful in the future to follow disease evolution through frequent blood checks, as well as to design therapies based on restoring normal levels of these altered microRNAs.
BMP9 and BMP10 inhibit VEGF expression and its proangiogenic effects, 48, 139 hence providing a rationale for the use of VEGF signaling targeting agents as pharmacological approaches for the treatment of patients with HHT. After a couple of satisfactory case studies with bevacizumab therapy on patients with HHT, 140 the VEGF-signaling inhibitors bevacizumab, ranibizumab, and pazopanib have, therefore, been included in several clinical trials (Table 2) .
This approach is also consistent with the detection of high levels of circulating VEGF in patients with HHT.
97,141 VEGF neutralization has been shown to prevent the formation of AVMs and improve the bleeding in preclinical mouse models of HHT. 76, 136, 137, 144, 175 Elevated levels of VEGF may, thus, represent a useful HHT therapeutic target but also biomarker surrogate for disease progression.
Several clinical studies are completed. One study evaluated the tolerance of 5 increasing doses of bevacizumab nasal spray in 5 groups of 8 patients with HHT. In this phase I doubleblind randomized placebo-controlled study (ELLIPSE study, NCT01507480), bevacizumab was well tolerated with no dose-limiting toxicity or severe adverse effects. However, no efficacy was observed at any of the tested doses. 145 A follow-up study coordinated by the same group included 3 administrations of bevacizumab nasal spray but as before did not provide improvements in epistaxis duration (NCT02106520) 147 . A different strategy was used by Riss et al 146 who performed a double-blinded randomized placebo-controlled trial with a single intranasal submucosal delivery of bevacizumab (NCT01314274). This study revealed a promising trend toward reduced number and severity of epistaxis. This was although a small cohort of 15 patients with great variation of epistaxis episodes and one single administration of bevacizumab to provide statistical significance. 146 Despite the slightly disappointing results, bevacizumab may still hold therapeutic promise, especially with the intranasal submucosal delivery.
The family of PI3Ks (phosphoinositide 3-kinases) has an important role in the development of cardiovascular diseases. The PI3Ks are involved in the regulation of essential cellular functions and thereby they modulate essential biological processes, which include metabolism, vascular homeostasis, and thrombogenicity.
176 Alk1 deletion leads to increased activation of the endothelial PI3K pathway, 175 which identified this pathway as a possible therapeutic target in HHT. Indeed, pharmacological inhibition of PI3K efficiently prevented AVM formation and reversed established AVMs in mouse models of HHT1 and HHT2, 76, 175 thus defining this as a potential novel therapy for vascular lesions in HHT.
Treatment of endoglin heterozygous mice with thalidomide was shown to reduce the severity of epistaxis, by increasing vascular smooth muscle cell coverage of the nasal mucocutaneous vessels. 153 This anti-inflammatory drug with antiangiogenic properties 150 is primarily used in the treatment of leprosy and multiple myeloma. 177 Thalidomide treatment has been successfully tested on small groups of patients with HHT 153, [178] [179] [180] and is currently included in clinical trials (Table 2 ; identifier, NCT01485224). The mechanism of action of thalidomide is still poorly understood 181 and little is known about its long-term benefits versus health risks. Thalidomide has well-documented teratogenic effects that seem to be directly linked to its antiangiogenic properties. 84, 150 Nevertheless, oral administration of low-dose thalidomide (50 mg/d starting dose and a maximum of 200 mg/d) appears to be safe and effective for the reduction of epistaxis in a cohort of 31 patients with HHT. 152 Three patients exhibited complete response (bleedings stopped), and 90% of the patients presented with partial responses. Also, the average hemoglobin levels were increased and the blood transfusion needs were reduced. 152 These positive observations should be validated in further studies with larger patient populations but represent an important hope for the treatment of patients with HHT. Data in the Table refer primarily to human pathology unless differently specified. BMP indicates bone morphogenetic protein; CCM, cerebral cavernous malformation; EC, endothelial cell; EndMT, endothelial-to-mesenchymal transition; HHT, hereditary hemorrhagic telangiectasia; KO, knockout; and TGF-β, transforming growth factor-β. Additional strategies for the treatment of patients with HHT include antifibrinolytic agents to reduce nosebleeds (eg, tranexamic acid), 156, 182 β-blockers to treat hemangiomas (eg, propranolol, timolol, and apo-timop), 159, 183 and hormonal therapies (eg, tamoxifen; Table 2) . 161 Clinical trials with tranexamic acid have been particularly successful with reduction of number and duration of epistaxis. 157, 158 Comparative studies have also taken place. For example, 1 study compared topical intranasal therapy of bevacizumab treatment with estriol and with tranexamic acid (NCT01408030). The trial did not, however, reveal a significant difference among the multiple treatment groups. 148 Because only one dose was tested for each drug, the benefit of this well-tolerated treatments cannot yet be completely excluded.
A novel treatment strategy for patients with HHT may include the rescue or stimulation of the suppressed BMP9/ALK1/ endoglin pathway. For this purpose, FK506 (tacrolimus)-a drug that activates the pathway-as been identified in a screen including Food and Drug Administration-approved drugs and bioactive compounds. This drug induces the restoration of BMPRII signaling and is being used for treatment of pulmonary arterial hypertension. 184 Tacrolimus was shown to increase expression of ALK1 and endoglin in ECs, 164 providing the rationale for a clinical trial on HHT that is already planned but not yet recruiting. This drug, targeting the cause rather than the symptoms as other strategies do, may be the key to an improvement in the quality of life of patients with HHT.
Cerebral Cavernous Malformation
CCM is a disease of the microvessels of the central nervous systems (ie, brain and retina) that form enlarged structures, known as cavernomas, that are often assembled into clusters (ie, mulberry lesions). 122 These abnormal formations are prone to leak blood and to rupture, which can cause headaches, seizures, focal neurological deficits, and hemorrhagic stroke. 125 Intriguingly, malformations typically originate from the vascular venous side, for reasons that remain unknown, although this might add information on the regulation of the arteriovenous specification. [5] [6] [7] 124 CCM occurs in both a sporadic form and a familiar form, with estimated prevalences of 1 in 200 individuals and <5 in 10 000 individuals, respectively, in terms of the general population. 122 Familial CCM is caused by a loss-of-function mutation in any 1 of 3 autosomal genes: CCM1/KRIT1, CCM2/ OSM, or CCM3/PDCD10. 122 CCM is a pseudodominant disease because although patients are heterozygous for mutation in the CCM genes, biallelic mutation of the CCM genes is observed locally in lesions. 127, 128 Biallelic CCM mutation has been reported also for lesions of patients with sporadic CCM. 102 The lesions in patients with sporadic CCM are prevalently single, whereas they are multiple in familial CCM. The penetrance of the clinical symptoms is incomplete, and depends strongly on the brain site of the malformations, with the brain stem location being the most symptomatic and dangerous site. Other predisposing factors, which remain essentially unknown at present, might significantly modify the clinical course of this disease, for example, low plasma levels of vitamin D 3 and non-high-density lipoprotein cholesterol 185 or polymorphisms that increase expression of the TLR4 gene or its coreceptor CD14, 199 which is associated with higher lesion burden. No specific pharmacological treatments are available to date for CCM. Surgery can be applied only to lesions in noncritical areas of the brain. 186 Ccm mutations in ECs are mainly responsible for the vascular malformations observed in CCM. Indeed, 
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endothelial-specific inducible ablation of any 1 of the 3 Ccm genes in newborn mice (Ccm EC-KO mice) induces vascular malformations in the central nervous system that are comparable with human cavernomas, also in terms of expression of molecular markers. [5] [6] [7] 124, 134 Smooth muscle cell or neuronspecific mutations of the Ccm genes do not induce cavernomas. 187 Constitutive ubiquitous mutation of the Ccm genes in mice also induces early embryonic lethality, with vascular defects. 188 Although the CCM genes code for unrelated proteins, their mutation causes remarkably similar phenotypes, although mutation of CCM3 produces the most serious symptoms. The similarity of the histological and molecular features of the lesions seen for the 3 different genotypes suggests common molecular mechanisms and targets. Indeed, the 3 CCM proteins can form a trimeric complex 188a,b that binds VE-cadherin at EC-to-cell junctions, through β-catenin. At endothelial junctions, CCM1 supports tethering and local activation of Rap1, with important consequences on the stabilization of the cortical actin cytoskeleton and of cell junctions. 132 Rap1 also inhibits the Rho-Rock pathway, 189 which is activated in Ccm1 or Ccm2-null ECs. 170 This supports contractions of the radial actin-myosin fibers and weakening of cell junctions.
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Deregulated Signaling of TGF-β/BMP
Several signaling pathways are deregulated in CCM-ablated ECs in culture and in cavernomas from mouse models and from patients. 191 Some of these dysfunctions are common to the 3 genotypes, whereas others are CCM-genotype specific (review 191 ). In cultured ECs, after inactivation of any one of the 3 CCM genes, activation of TGF-β/BMP signaling is seen by the nuclear accumulation of pSmad3 and pSmad1. These data were confirmed in vivo in ECs lining experimental murine cavernomas in Ccm1 EC-KO and Ccm3 EC-KO mice and in cavernoma samples from patients with familial CCM and sporadic CCM. [5] [6] [7] 134 Enhanced TGF-β/BMP signaling after ablation of any one of the CCM genes is an EC-autonomous response because it can be observed also in ECs in culture. 5, 7, 134 At least 2 different mechanisms have been identified as responsible for this increase in signaling: higher and sustained response to exogenous TGF-β by CCM-deficient ECs and production of endogenous BMP ligands. CCM-ablated ECs also showed increased synthesis of endogenous proangiogenic BMP6 and BMP2. 5 This is controlled, in part, through a Klf4-driven transcriptional mechanism. 134 Enhanced expression of BMP6 in and around the ECs that line the malformations was also observed in vivo, both in mouse models and in patients. 134 The other BMPs are not upregulated, at least in in vitro-cultured CCM-deficient ECs. Thus, consistent with several data on cultured CCM-deficient ECs, CCM mouse models and patients with CCM underline the role of TGF-β/BMP activation in the development of the disease. Pharmacological inhibitors of either TGF-β or BMPs reduce the number and size of the malformations (Table 2) ; however, genetic inactivation of both CCM and BMP6/2 or of TGF-β signaling pathway has not yet been reported. Indeed, the results of this approach would be particularly difficult to interpret because it is known that BMP6 and 2 can be reciprocally compensatory (for instance 192 ), and the wide spectrum of TGF-β activities on ECs in vivo (above) would prevent a simple and univocal interpretation of the results.
Endothelial-to-Mesenchymal Transition
Enhanced TGF-β/BMP signaling contributes to the acquisition of a different cell phenotype in the process known as EndMT. 193, 194 In tumors and during development, TGF-β can induce an analogous process in epithelial cells, known as epithelial-to-mesenchymal transition. 195, 196 EndMT is characterized by the disorganization of EC-to-cell contacts 5, 7, 124, 134 loss of apical-to-basal polarity, 197 and expression of stem cell/mesenchymal cell markers. 5 In the ECs that line CCM cavernomas, the process of EndMT is incomplete. These ECs maintain endothelial markers, such as claudin5 and VE-cadherin, whereas they show upregulation of stem cell/mesenchymal markers. 194 This partial switch to mesenchymal cells has also been frequently described for epithelial cells undergoing epithelial-to-mesenchymal transition in vivo. 198 Inhibitors of TGF-β/BMP signaling that act on type I TGF-β (eg, LY-364947 and SB-431542) and type I BMP receptors (eg, dorsomorphin) can inhibit and revert EndMT in cultured Ccm-null ECs. These inhibitors also reduce the number and dimensions of cavernomas lesions in the preclinical Ccm1 EC-KO mouse model (Table 2) . 5 Consistently, addition of exogenous BMP6 and BMP2 to cultured wild-type ECs induces EndMT. This indicates that in ECs, activation of both signaling arms of TGF-β/BMP is implicated the development of EndMT and cavernomas.
Klf4 Transcription Factor
A key mediator in the expression of the EndMT phenotype in Ccm1-null and Ccm3-null ECs is the transcription factor Klf4. 5, 134 Klf4 and Klf2 173 are overexpressed early after ablation of any one of the 3 Ccm genes, both in vitro and in vivo. Mice that carry double mutation for Ccm and Klf4 or Klf2 have greatly reduced numbers of vascular lesions in the brain and retina, 134, 173 in parallel with inhibition of EndMT markers. 134 These double-KO mice also have a normal life span in comparison with the early mortality of CCM-deficient mice.
The small molecule drugs LY-364947, SB-431542, and dorsomorphin target TGF-βRIs (ALK4, ALK5, and ALK7) and BMPRIs (ALK1, ALK2, ALK3, and ALK6), inhibit the expression of Klf4 and the EndMT phenotype.
5 BMP stimulation in cultured human umbilical vein ECs upregulates Klf4, among other genes. 59 Therefore, Klf4 appears to be a target of TGF-β/BMP signaling.
However, Klf4 can be induced also through other independent pathways. In particular, Klf4 can be induced by the MEKK3/MEK5/ERK5 pathway, which is downstream of several receptor tyrosine kinase signaling pathways, and is activated on ablation of any of the Ccm genes. 134,173,198a The MEKK3/MEK5/ERK5 pathway induces activation of the transcription factors Mef2a and Mef2c, which, in turn, upregulate the expression of Klf4. 134 Klf4 itself upregulates the expression of EndMT markers, in some case through direct activation of their promoters (eg, Sca1 and S100a4
134
). In addition, Klf4 can induce BMP6 expression, which, in turn, activates the TGF-β/ BMP pathway, thus establishing a positive signaling loop.
A recent study showed that the gut microbiome (more specifically Gram-negative bacteria) and lipopolysaccharide can accelerate the formation of CCM lesions by activation of TLR4 or the coreceptor CD14. These receptors can activate the MEKK-Klf2/4 pathway, which would in turn increase the lesion burden both in mice and humans; this opens up a new field of investigation. 199 Although necessary, the overexpression of Klf4/2 is not sufficient to induce the formation of cavernomas in the central nervous system. Mice that overexpress Klf4 in ECs will only show reduced atherosclerotic burden with reduced infiltration of inflammatory cells if they are fed a high-fat diet; however, they do not develop cavernomas.
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Cross talk With Other Signaling Pathways
The study of the kinetics of development of CCM can help to define the reciprocal interactions between the signaling pathways and their specific roles in disease progression. In Ccm3 EC-KO mice crossed with β-catenin signaling reporter mice, 7 we showed that in the cavernomas of retina and brain, β-catenin is activated first at 3 dpn and only subsequently, at 9 dpn, it is downregulated, when TGF-β/Smad signaling is increased. These observations support the idea of reciprocal regulation of these 2 pathways, as reported in other systems, such as during embryo and tumor development. 201, 202 The sequential activation of these 2 pathways has also been widely described in different systems. 202, 203 Coexpression of EndMT markers and β-catenin-driven reporter (ie, β-galactosidase) was observed at 3 dpn in 80% of the ECs that lined the cavernomas, whereas it decreased to 30% at later stages. However, expression of the EndMT markers was maintained constant in ECs of the cavernomas from 3 dpn to 9 dpn. This suggests that a mechanism distinct from β-catenin-driven transcription supports the EndMT phenotype at later stages of cavernoma development. pSmad1 and pSmad3 were low in early lesions (ie, 3 dpn), whereas they increased substantially in late lesions (ie, 9 dpn), which suggests that TGF-β/BMP contributes to the maintenance and progression of these cavernomas 7 consistently with what has been observed also in human CCM malformations. 6 Sustained β-catenin-driven transcription in cultured ECs can per se directly induce expression of both Klf4 and EndMT mesenchymal markers, as observed through expression of a constitutively active form of β-catenin (Lef-N-CTA 7, 204, 205 ). In addition, a dominant-negative form of Tcf4 that specifically prevents β-catenin-driven transcription 206, 207 inhibits expression of Klf4 and EndMT markers in Ccm3-null ECs in culture. 7 Activation of β-catenin signaling is an EC-autonomous response because it can be observed in cultured ECs after ablation of CCM3. This pathway seems to be different from Wnt activation because it is not affected by inhibitors of Wnt synthesis and does not induce Wnt receptor Lrp6/5 phosphorylation. 7 In Ccm1-null and Ccm3-null ECs, adherens cell-to-cell junctions are dismantled at the early stages of gene inactivation. 7, 132, 174 This process is accompanied by partial dissociation of β-catenin from junctions with its nuclear translocation and an increase in transcriptional activity. 7, 208 It is possible, therefore, that under these particular conditions, β-catenin shuttles from junctions to the nucleus without the need for any direct Wnt activation of the cells, as reported recently for selected epithelial somite progenitor cells during myogenesis. 209 Disorganization of endothelial junctions is supported also by enhanced secretion of angiopoietin-2 in CCM3-deficient ECs as recently reported byZhou et al 174 in vitro and in vivo. The increased exocytosis of angiopoietin-2 is a CCM3-KOspecific phenotype of ECs of the central nervous system. Regulation of the endocytic recycling of the apical membrane appears a unique property of CCM3 that contributes to the organization of tubular organs in Caenorhabditis elegans 210 and in Drosophila. 211 Angiopoietin-2/phospho-Tie2 signaling can destabilize endothelial junctions 212 ; however, the cross talk with other signaling pathways activated in CCM3-deficient ECs, among which TGF-β/BMP and β-catenin is not known at the present, as also commented by Zhou et al. 174 The observation by Zhou et al 174 supports a novel therapeutic approach specific for CCM3 (Table 2) .
Another study confirmed the role of Klf2/4 transcription factors in the development of CCM but did not observe β-catenin or Smad signaling in ECs of Ccm-deficient mouse vessels. However, they did not study EndMT markers directly. 173 These differences may be explained by the use of a different experimental model. The Ccm1 and Ccm2 KO models used by Zhou et al 173 exhibit a much slower progression of the disease (total lethality within 30-40 postnatal days in comparison with 11-14 postnatal days) than the Ccm1 and 3 KO models used in previous articles. 5, 134 This is likely because of the use of a mixed genetic background by Zhou et al. 173 Known and unknown strain-specific modifiers may substantially change the evolution of the disease, the expression of markers, and kinetics of the triggering pathways. In addition, as discussed previously, 194 the development of EndMT is a dynamic process, which follows a specific time course. We reported previously that Smad activation is a relatively late phenomenon and it is likely that if the progression of the lesion is slow, detection of Smad phosphorylation may be missed. 7 Apart from specific technical considerations, the most important question is what occurs in patients. Studies of human tissues demonstrated that not only both Klf4 and pSmad3 were upregulated in the endothelium lining human familial and sporadic CCM malformations but that this was accompanied by a substantial upregulation of EndMT markers, such as S100a4, αSMA, fibronectin, N-cadherin, and Id1. 6 Overall, these data confirm the importance of Smad signaling and EndMT switch in the endothelium lining CCM malformations in human patients.
Other pathways may also contribute to the development and evolution of CCM, including Delta-Notch, 213 β1-integrins, 214 inhibition of autophagy, 215 oxygen radicals 216 and oxidative stress, 217 angiopoietin 2, 174 and others. However, their role in the induction of EndMT has not yet been investigated.
A recent article 199 also reported that the microbioma composition may strongly affect the evolution and bleeding of CCM. This effect is likely because of the release of small concentration of endotoxin by Gram-negative bacteria. Lipopolysaccharides would in turn trigger endothelial inflammatory reaction and aggravate cavernoma progression. Whether this reaction may be influenced by the constitutive expression of TGF-β in the brain is unknown. September 29, 2017
Pharmacological Targeting of TGF-β/BMP Signaling in CCM
The definition of a pharmacological strategy is an urgent need for patients with CCM because there remains a lack of any specific pharmacological therapy. These patients can experience serious focal neurological deficits, which strongly impact on their quality of life. 186 Whether ALK1 and endoglin signaling is enhanced in CCM is not currently known. However, because Ccm1 EC-KO mice benefit from treatment with dorsomorphin (a BMPRI inhibitor of ALK1, 2, 3, and 6; Table 2 ), it would seem that targeting of BMP9/ALK1/endoglin might hold therapeutic promise for CCM. There are indeed multiple inhibitors for ALK1 and endoglin that are currently undergoing clinical trials. These drugs have been efficacious in the treatment of different types of cancer where ALK1 and endoglin expression becomes upregulated during the angiogenic switch in tumor progression. [218] [219] [220] [221] [222] MiR-27b has recently been shown to positively regulate TGF-β-induced EndMT in microvascular ECs. 223 Inhibition of miR-27b further suppressed TGF-β-mediated induction of mesenchymal gene upregulation. If this particular microR-NA is of importance in CCM, and if it can be detected in the plasma of patients with CCM, it might serve as an important therapeutic and diagnostic tool.
At present, therefore, TGF-β/BMP signaling remains an interesting potential target to control CCM. However, because of its relevance in many physiological functions, the targeting of the TGF-β/BMP pathway requires further investigation and careful evaluation of the benefit/risk ratio before being proposed for testing in clinical trials with patients with CCM. Drugs that target other signaling mediators activated in CCMnull ECs, such as Rho-Rock, β-catenin, Klf4, multiple kinases, and superoxides, have been shown to inhibit lesion burden in murine models of CCM. 191 However, the clinical effects of these inhibitors remain to be evaluated. 186 A recent report by Tang et al 199 is of particular interest here, as discussed above. This study implicated the microbiome, endotoxin, and TLR4/CD14 in CCM progression. Inhibitors of endotoxin signaling through TLR4 might be effective for the reduction of both existing and early developing lesions. However, manipulation of the microbiome might be even more attractive because this might be a lasting intervention, possibly with limited side effects. It might also be of interest to consider the combination of different inhibitors that target the different pathways at the subsequent stages of disease progression. For instance, inhibition of β-catenin or of cell-to-cell junction disassembly might prove effective at the early stages of the formation of cavernomas, whereas targeting TGF-β/ BMP might inhibit their maintenance and progression.
It is important, although, to underline that the most relevant and desired effects of therapies for CCM in terms of both hereditary and sporadic disease is the induction of the regression of the malformations, more than the reduction of new lesion formation. 224 To date, few, if any, of the inhibitors under study have shown any effects toward regression of the malformations. It is, therefore, crucial to use slow progressive murine models of CCM to determine whether treatments targeting the TGF-β/BMP pathway can stabilize preexisting lesions and further, can induce their regression.
Bridging Aspects Between HHT and CCM
HHT and CCM display some phenotypic similarities (Table 1) . However, the molecular defects supporting the convergent phenotypic traits in the 2 pathologies appear different or remain to be explored.
A common feature in the genetics of CCM and HHT is that mutations in CCMs, ENG, or ALK1 genes are systemically heterozygous in familial patients. CCM lesions are characterized by a somatic mutation in the second CCM allele with acquisition of homozygous genotype. [127] [128] [129] Homozygous CCM mutation is also observed in sporadic patients. 102 It remains to be assessed whether loss-of-heterozigosity represents the local second hit that induces HHT lesions (discussion 84 ). A resemblance between HHT and CCM is the abnormal venous morphology of both types of lesions (Table 1) . In HHT, the mechanism of initiation of the lesions has been defined in detail. ECs in arterioles do not respond to blood flow because of the lack of the flow-sensor endoglin and acquire venous markers. 76, 77, 225 Although in CCM, the origin of the lesion appears venous, 5, 7, 124 this subject deserves more detailed analysis, as well as the role of flow in CCM malformations.
On this topic, it is intriguing that Klf2 and Klf4, which are central inducers of CCM lesions, 134, 173 are mechanosensitive genes and mediate endothelial atheroprotective responses to shear stress. 226, 227 However, deletion of any CCM gene induces a mutated phenotype in ECs also under static conditions (both in 2-and 3-dimensional cultures). 5, 7, 124, 132, 197 The role of Klf2 and Klf4 in HHT has not been thoroughly explored. Importantly, the flow-regulated transcript Klf2 was upregulated on loss of endoglin in zebrafish postcardinal vein only. 77 In contrast, it remained unchanged in endoglin-deficient human umbilical vein ECs either in static conditions or under shear stress. 77 This indicates that the shear stress-sensing defect in endoglin-deficient ECs is not upstream of Klf2. 77 One of the first events in the development of CCM is the disorganization of EC junctions, where VE-cadherin expression and localization is strongly affected. Given that increased vessel leakage is a feature of HHT, it is possible that the junctions are also altered in this pathology. We previously reported that VE-cadherin is a positive and EC-specific regulator for TGF-β signaling, with the promotion of the receptor complex assembly. 228 This suggests that in HHT, where critical members of TGF-β/BMP signaling are reduced, a concomitant reduction in VE-cadherin might exacerbate the condition and cause vascular fragility and hemorrhaging, similar to CCM. Interestingly, BMP6 has been shown to induce increased permeability of human ECs by inducing internalization of VE-cadherin and cSrc-dependent phosphorylation and junctional remodeling. 229 Also, BMP-dependent physical interaction of VE-cadherin with ALK2 and BMPRII results in stabilization of the receptor complex and, therefore, downstream Smad signaling. 229 Whether disturbance of BMP9/10 signaling via ALK1 in HHT also affects cell junctions is still to be confirmed.
Interestingly, a group of genes deregulated in HHT patient telangiectasis appears to be regulated by differentially expressed long noncoding RNAs. 93 Among these, there is also CCM2. On the other side, a genome-wide sequencing study comparing brain stem biopsies from CCM patients with healthy brains revealed 5 significantly downregulated miRNAs, among them let-7b predicted to target endoglin. 230 The molecular connections between CCM and HHT may be of particular interest in the case of HHT1, because loss of endoglin is the main cause for brain AVMs, occurring in 10% of patients with HHT 99 and which have some morphological similarities to CCM lesions. Loss-of-function of ALK1 can also induce the emergence of cerebral AVMs, although much less frequently. 231 However, much like the enhanced proliferative status of ECs within CCM lesions, Alk1-deficient ECs show greater migratory and invasive characteristics in vivo, similar to CCM1/2-deficient cells. 85 Detailed characterization of the molecular defects in CCM and HHT will allow a more accurate comparison of the 2 pathologies at the molecular level.
Conclusions
Overall, a comparison of HHT and CCM shows a complex network of signaling pathways that leads to these 2 types of vascular malformations. Through the analysis of the common features, such as fusion of multiple capillaries, enlargement of the venous lumen, vascular fragility, altered response to blood flow, and others, it is possible to identify common mechanisms. For instance, deregulated TGF-β/BMP signaling in ECs contributes to the mutated phenotype in both CCM and HHT. However, it is likely that the aberrant activation or inhibition of multiple signaling pathways and their potential abnormal cross talk are responsible for the overall development of these diseases.
It is likely that none of the discussed signaling pathways is sufficient per se to induce the vascular pathological phenotype. For instance, in CCM, most of the signaling cascades converge on enhanced expression of the transcription factors Klf4/2, which, however, requires a mutated cellular environment to induce the malformations. Nevertheless, if the concerted action of different signals is required for the disease to develop, inhibition of a single pathway might still be effective. Common mechanisms might underlie the formation of different vascular syndromes. For instance, expression profiling of long noncoding RNAs in the nasal mucosa of patients with HHT identified long noncoding RNAs that regulate CAV1 (mutated in pulmonary arterial hypertension), CCM2 (mutated in CCM), and RASA1 (mutated in capillary malformation-AVM), among others 93 suggesting some common traits in these different vascular syndromes.
Next-generation sequencing will prove useful for efficient characterization of vascular genetic diseases, and to potentially identify similarities with other types of vascular pathologies. 110, 232 For instance, next-generation sequencing has been created to increase the efficiency of genetic diagnosis in patients with HHT and in other vascular alterations with partial phenotype/genotype overlapping with HHT (ENG, ALK1, SMAD4, and BMP9), such as pulmonary arterial hypertension (BMPR2, CAV1, and ALK1), CCM (CCM1, CCM2, and CCM3) and capillary malformation-AVM syndrome, which is caused by mutations in RASA1. 107 This initiative is currently under a validation phase but may represent an important advancement not only toward improvement in clinical diagnostics but also lending perspectives to common features and possibly common therapeutics for different diseases. 
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